Alcon is going it alone following a spin-out from Swiss pharma giant Novartis. The eye-care device business officially listed on the SIX Stock Exchange on April 9 with a total market capitalization of around $28bn, making it Switzerland's biggest stock deal in a decade.
Novartis has completed the spin-off of eye-care devices business Alcon in Switzerland's biggest stock deal in a decade. Alcon officially listed on the SIX Swiss Stock Exchange April 9, with a market capitalization of over $25bn.
The Geneva-based company is the largest ophthalmic device maker in the world, with complementary businesses in surgical and vision care, and a global presence in 74 countries
Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.
Seonix launched SightScore, the first clinical polygenic risk score test for glaucoma available in the US, and plans to introduce more genetic-based tests for eye conditions such as macular degeneration.
The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.
The program, which brings together innovators and device industry stakeholders, helps ease the path to market for novel devices.
Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.
NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.
At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.
